Samjin Pharmaceutical삼진제약
005500 · KOSPI · ₩005500 · 삼진제약
₩19,250▼ ₩120 (0.62%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 38.1% | 40.5% | 41.8% | 39.9% | 43.0% | 47.1% |
| Operating margin | 7.9% | 8.7% | 10.3% | 7.0% | 8.5% | 13.6% |
| Net margin | 7.0% | 7.8% | 12.7% | 6.5% | 7.7% | 11.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +0.7% | +0.3% | +5.6% | +6.6% | +9.6% | — |
| Operating income growth | −7.7% | −15.3% | +54.4% | −12.1% | −31.3% | — |
| Net income growth | −9.5% | −38.4% | +107.5% | −10.4% | −25.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 7.4% | 8.8% | 14.9% | 7.0% | 8.3% | 12.1% |
| Return on assets | 4.6% | 5.4% | 9.3% | 4.6% | 5.7% | 8.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 59.6% | 62.0% | 62.5% | 58.2% | 47.4% | 42.0% |
| Net debt to equity | 2.4% | 41.9% | 44.5% | 43.0% | 27.8% | 17.9% |
| Current ratio | 132.2% | 130.2% | 100.0% | 101.1% | 164.4% | 282.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Samjin Pharmaceutical / 삼진제약 / 005500 / KRX:005500
Source: KRX statistical information